The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Jeffrey Jones on the Efficacy of Venetoclax in Treatment for CLL

Jeffrey Jones, MD
Published Online: 5:49 PM, Fri December 11, 2015


Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL). Jones says both idelalisib and ibrutinib have been highly effective in the majority of relapsed/refractory CLL.


Jones says that while idelalisib and ibrutinib have been effective overall, there is a small group of patients who cannot receieve the treatment. He says that a different option for patients who cannot undergo those treatments are BCL-2 inhibitors like venetoclax. He adds that in a recent study, venetoclax has proven to be effective in the patient population with CLL who cannot receieve idelalisib and ibrutinib due to toxiticies or high-risk genetic features.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.